Dermatitis News

Seborrheic dermatitis was improved in patients treated with topical roflumilast foam in a phase 2 clinical trial, Arcutis Biotherapeutics announced in a press release.

Management of ocular surface disorders may be needed for patients who are on dupilumab to treat atopic dermatitis, according to a presentation at the American Academy of Dermatology virtual meeting.

The European Medicines Agency has recommended an extension to baricitinib’s indications to include the treatment of moderate to severe atopic dermatitis, according to a press release.

Arcutis Biotherapeutics will begin phase 3 trials of ARQ-151 for the treatment of atopic dermatitis, according to a press release.

Among a large cohort of patients with atopic dermatitis, treatment with topical calcineurin inhibitors demonstrated no association with elevated risk for keratinocyte carcinoma, according to a study.

The FDA has granted fast track designation to delgocitinib cream for the potential treatment of moderate to severe chronic hand eczema in adults, Leo Pharma announced in a press release.

Tapinarof cream was associated with significant improvement as assessed by Investigator Global Assessment in a cohort of adults and adolescents with atopic dermatitis, according to a study.

Distinct immune and barrier signatures for atopic dermatitis and psoriasis were identified using RNA-sequencing tape strips, according to a study.

Two daily dosing regimens of abrocitinib were associated with favorable efficacy and safety outcomes in patients with moderate to severe atopic dermatitis.

Atopic eczema carried no association with overall cancer risk but was associated with non-Hodgkin and Hodgkin lymphoma, according to results of two large population-based studies.